AFMD - アフィメド (Affimed N.V.) アフィメド

 AFMDのチャート


 AFMDの企業情報

symbol AFMD
会社名 Affimed N.V. (アフィメド)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes FM13 AFM11 AFM21 AFM22 AFM24 TandAb and Trispecific Abs. It has started recruitment for Phase IIa clinical trial of AFM13 in patients with Hodgkin Lymphoma. It has initiated a Phase I clinical trial of AFM11 in patients with non-Hodgkin Lymphoma. AFM21 is in preclinical development. AFM22 which is an Epidermal Growth Factor Receptor variant III (EGFRvIII)/CD16A NK-cell TandAb is in preclinical development. AFM24 is an additional CD16A NK-cell TandAb targeting a validated solid tumor target EGFR-wild type. It is developing Trispecific Abs for treating multiple myeloma and CD33/CD3-specific T-cell TandAb to treat acute myeloid leukemia.   アフィメドはドイツのバイオ医薬品会社の持株会社。同社は2000年設立。ハイデルベルクのドイツがん研究センタ―で開発された技術をもとに、腫瘍細胞への自己免疫力を高める革新的なアプロ―チによるがん治療法の研究、開発、商品化に従事。開発中の製品にAFM13、AFM11、AFM21を含む。   Affimed is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company's proprietary ROCK® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK platform predictably generates customized innate cell engager (ICE®) molecules, which use patients' immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE®. Headquartered in Heidelberg, Germany, with offices in New York, New York, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients' lives.
本社所在地 Technologiepark Im Neuenheimer Feld 582 Heidelberg 69120 DEU
代表者氏名 Thomas Hecht トーマス・ヘクト
代表者役職名 Chairman of the Supervisory Board
電話番号 +49 6221-67-4360
設立年月日 41760
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数
url www.affimed.com
nasdaq_url https://www.nasdaq.com/symbol/afmd
adr_tso
EBITDA EBITDA(百万ドル) -34.24747
終値(lastsale) 4.62
時価総額(marketcap) 288242114.16
時価総額 時価総額(百万ドル) 218.36520
売上高 売上高(百万ドル) 2.05078
企業価値(EV) 企業価値(EV)(百万ドル) 170.73193
当期純利益 当期純利益(百万ドル) -35.31480
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Affimed NV revenues decreased 25% to EUR682K. Net loss increased 3% to EUR16.2M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development expenses - Bala increase of 23% to EUR13.1M (expense) Interest Expense Net increase from EUR168K to EUR466K (expense).

 AFMDのテクニカル分析


 AFMDのニュース

   Affimed N.V. Shares Fall 1.3% Below Previous 52-Week Low - Market Mover  2022/01/11 04:20:14 Kwhen Finance
Affimed N.V. (AFMD) shares closed 1.3% lower than its previous 52 week low, giving the company a market cap of $473M. The stock is currently down 12.7% year-to-date, down 22.0% over the past 12 months, and up 109.6% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 54.0% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.5. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 51.4% The company's stock price performance over the past 12 months beats the peer average by -12.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Affimed N.V. Shares Near 52-Week Low - Market Mover  2022/01/10 08:55:49 Kwhen Finance
Affimed N.V. (AFMD) shares closed today at 0.8% above its 52 week low of $4.78, giving the company a market cap of $473M. The stock is currently down 12.7% year-to-date, down 22.0% over the past 12 months, and up 119.1% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 12.4% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.5. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 51.4% The company's stock price performance over the past 12 months beats the peer average by -12.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Affimed N.V. Shares Near 52-Week Low - Market Mover  2022/01/08 04:28:39 Kwhen Finance
Affimed N.V. (AFMD) shares closed today at 0.8% above its 52 week low of $4.78, giving the company a market cap of $495M. The stock is currently down 8.7% year-to-date, down 14.9% over the past 12 months, and up 129.1% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.7%. Trading Activity Trading volume this week was 12.4% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.5. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 6.7% lower than its 5-day moving average, 12.8% lower than its 20-day moving average, and 22.1% lower than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 23.6% The company's stock price performance over the past 12 months beats the peer average by -27.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Affimed Announces Completion of Enrollment in REDIRECT, the Registration-Directed Study of AFM13 in PTCL, and Provides Business Update  2022/01/06 11:30:00 Benzinga
Enrollment of REDIRECT study (AFM13-202) is completed; topline clinical readout expected in 2H 2022 FDA approves protocol amendment to allow for (i) enrollment of up to 40 patients at the highest dose level, and (ii) treatment of patients with more than two cycles in the investigator sponsored trial of cord blood-derived natural killer (cbNK) cells pre-complexed with AFM13 (AFM13-104) Broad development strategy launched for AFM24 enrollment initiated in three studies addressing major EGFR-expressing solid tumor indications including non-small cell lung and colorectal cancer For AFM28 a first in human study initiation is planned for second half of 2022 Cash position provides funding into 2H 2023 HEIDELBERG, Germany, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ: AFMD ), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has completed enrollment in the REDIRECT study and provided a business update.
   Why To Invest In Affimed N.V. (NASDAQ: AFMD) Stock?  2021/12/06 12:30:00 Marketing Sentinel
In the last trading session, 3.35 million Affimed N.V. (NASDAQ:AFMD) shares changed hands as the companys beta touched 2.59. With the companys per share price at $6.07 changed hands at -$0.51 or -7.75% during last session, the market valuation stood at $787.83M. AFMDs last price was a discount, traded about -93.41% off its 52-week high Why To Invest In Affimed N.V. (NASDAQ: AFMD) Stock? Read More »
   Buy, Sell Or Hold Affimed N.V. (NASDAQ:AFMD) At $6.75?  2021/12/02 12:00:00 Marketing Sentinel
In last trading session, Affimed N.V. (NASDAQ:AFMD) saw 2.08 million shares changing hands with its beta currently measuring 2.57. Companys recent per share price level of $6.75 trading at -$0.07 or -1.03% at ring of the bell on the day assigns it a market valuation of $817.83M. That closing price of AFMDs stock is at Buy, Sell Or Hold Affimed N.V. (NASDAQ:AFMD) At $6.75? Read More »
   Affimed''s Lymphoma Candidate Shows 100% Objective Response Rate At Highest Dose  2021/11/22 14:47:30 Benzinga
Affimed NV (NASDAQ: AFMD ) has announced interim clinical results from the investigator-initiated Phase 1/2 study evaluating cbNK cells pre-complexed with Affimed''s innate cell engager (ICE) AFM13. Eighteen patients with CD30-positive relapsed or refractory Hodgkin and non-Hodgkin lymphomas were treated with the combination of cbNK cells pre-complexed with AFM13. 16 Full story available on Benzinga.com
   Thinking about buying stock in Astra Space, PainReform, Vonage, Affimed NV, or Provention Bio?  2021/11/22 13:30:00 Benzinga
NEW YORK , Nov. 22, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ASTR, PRFX, VG, AFMD, and PRVB. Full story available on Benzinga.com
   Affimed N.V. (NASDAQ: AFMD) Stock: Now At 40.38% Gain Since Low, This Stock Just Hasnt Warmed Up  2021/11/15 13:00:00 Stocks Register
Affimed N.V. (NASDAQ:AFMD) price closed higher on Friday, November 12, jumping 0.68% above its previous close. >> 7 Top Picks for the Post-Pandemic Economy > 7 Top Picks for the Post-Pandemic Economy
   Hodgkins Lymphoma Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Affimed Therapeutics, ACD Therapeutics, Cstone Pharmaceuticals and Many Others  2021/06/14 21:26:01 AB Newswire
   Affimed Announces Virtual Annual General Meeting of Shareholders  2021/05/20 20:30:00 GlobeNewswire
Heidelberg, Germany, May 20, 2021 Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its 2021 Annual General Meeting of Shareholders (the Annual Meeting) will be held on June 15, 2021 at 17:30 PM CET (11:30 AM EDT). Due to the continuing COVID-19 pandemic and out of concern for the health and safety of shareholders and other attendees, the Annual Meeting will be held virtually and can be followed by visiting www.virtualshareholdermeeting.com/AFMD2021 , in accordance with the instructions provided in the notice of the meeting. Shareholders will not be able to attend the Annual Meeting in person.
   Affimed N.V. (AFMD) falls 1.96% for May 19  2021/05/19 22:00:27 Equities
Affimed N.V. (NASDAQ: AFMD) shares fell -1.96% to end trading Wednesday at $9.50 per share - a net change of $-0.19. Shares traded between $9.64 and $9.19 throughout the day. 940735 shares of Affimed N.V. exchanged hands. Visit Affimed N.V.s profile for more information. About The Nasdaq Stock Market The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world\''s leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook. To get more information on Affimed N.V. and to follow the companys latest updates, you can visit the companys profile page here: Affimed N.V.s Profile . For more news on the financial markets be sure to visit Equities News . Also, dont forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week. Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by Barchart as of 4:30pm ET on the day of publication.
   Affimed NV Stock Is Estimated To Be Significantly Overvalued  2021/05/15 07:12:07 GuruFocus
Related Stocks: AFMD ,
   Affimed''s AFM13 In Combination With NK Cells Show Improved Tumor Recognition, Killing In Preclinical Studies  2021/05/14 13:30:10 Benzinga
Affimed NV (NASDAQ: AFMD ) has announced the publication of in vitro and in vivo research of its lead innate cell engager (ICE), AFM13 (CD16A/CD30), combined with healthy donor-derived Natural killer (NK) cells, in Clinical Cancer Research. The preclinical data demonstrated that AFM13 Full story available on Benzinga.com

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アフィメド AFMD Affimed N.V.)

 twitter  (公式ツイッターやCEOツイッターなど)